Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma
NCT05790200
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG:
Cadonilimab
Sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology